Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Ozan, Salim"'
Autor:
Özgür Mehtap, Tayfur Toptas, Mehmet Sinan Dal, Güner Hayri Özsan, Nigün Sayinalp, Güray Saydam, Mehmet Ali Uçar, Hakki Onur Kirgizlar, Ozan Salim, Atakan Tekinalp, Fahir Özkalemkaş, Funda Pepedil Tanrikulu, Olga Meltem Akay, Emrah Kiliçaslan, Semra Paydas, Sinem Civriz, Mehmet Yilmaz, Volkan Karakuş, Fatma Geçgel, Tahir Darçin, Elçin Erdoğan, Erkin Çinar, Fatma Keklik Karadağ, Ünal Ataş, Vildan Gürsoy, Salih Sertaç Durusoy, Elif Birtaş Ateşoğlu, Anil Tombak, Nurhilal Büyükkurt, Muhit Özcan, Fevzi Altuntaş, Ahmet Burhan Ferhanoğlu
Publikováno v:
HemaSphere, Vol 7, p e566791c (2023)
Externí odkaz:
https://doaj.org/article/e9b3c75689fe4673b443fbabb3a75f21
Autor:
Fergün Yılmaz, Nur Soyer, Güldane Cengiz Seval, Sinem Civriz Bozdağ, Pervin Topcuoğlu, Ali Ünal, Leylagül Kaynar, Gökhan Özgür, Gülsan Türköz Sucak, Hakan Göker, Mustafa Velet, Hakan Özdoğu, Mehmet Yılmaz, Emin Kaya, Ozan Salim, Burak Deveci, İhsan Karadoğan, Güray Saydam, Fahri Şahin, Filiz Vural
Publikováno v:
Turkish Journal of Hematology, Vol 38, Iss 3, Pp 195-203 (2021)
Objective: Although inhibition of the complement system at different steps is a promising therapy modality in patients with paroxysmal nocturnal hemoglobinuria (PNH), allogeneic hematopoietic stem cell transplantation (HCT) is still the only curative
Externí odkaz:
https://doaj.org/article/5bce8903a2b2414e88326fb73088f77a
Autor:
Ozan Salim
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 42, Iss , Pp 15- (2020)
Externí odkaz:
https://doaj.org/article/8cb38147ec604466aaee54ba3224cfee
Publikováno v:
Nutrition and Cancer. 75:591-598
The prognostic value of the geriatric nutritional risk index (GNRI) is not clear in patients with diffuse large B-cell lymphoma (DLBCL). This study was designed to analyze the GNRI in DLBCL patients and to investigate its prognostic value in DLBCL. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a1fe155d42a01363aae14fa6d2c7f64
https://doi.org/10.1080/01635581.2022.2142248
https://doi.org/10.1080/01635581.2022.2142248
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:702-707
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11dcade5c572a84d6dbeedd3a3fce73f
https://doi.org/10.1016/j.clml.2022.04.018
https://doi.org/10.1016/j.clml.2022.04.018
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 13, Iss 2, p OL01 (2019)
Externí odkaz:
https://doaj.org/article/154a8cd536594162a0708e40a6735f1a
Autor:
Anıl Tombak, Mehmet Ali Uçar, Aydan Akdeniz, Eyüp Naci Tiftik, Deniz Gören Şahin, Olga Meltem Akay, Murat Yıldırım, Oral Nevruz, Cem Kis, Emel Gürkan, Şerife Medeni Solmaz, Mehmet Ali Özcan, Rahşan Yıldırım, İlhami Berber, Mehmet Ali Erkurt, Tülin Fıratlı Tuğlular, Pınar Tarkun, İrfan Yavaşoğlu, Mehmet Hilmi Doğu, İsmail Sarı, Mustafa Merter, Muhit Özcan, Esra Yıldızhan, Leylagül Kaynar, Özgür Mehtap, Ayşe Uysal, Fahri Şahin, Ozan Salim, Mehmet Ali Sungur
Publikováno v:
Turkish Journal of Hematology, Vol 33, Iss 4, Pp 273-280 (2016)
Objective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective m
Externí odkaz:
https://doaj.org/article/991999bdfbb345eea13143fc24d2544e
Autor:
Bahar Akkaya, Ozan Salim, Hampar Akkaya, Mualla Ozcan, Orhan Kemal Yucel, Ramazan Erdem, Utku Iltar, Levent Undar
Publikováno v:
Indian Journal of Pathology and Microbiology, Vol 59, Iss 1, Pp 41-46 (2016)
Purpose: Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with marked biologic heterogeneity. MYC and BCL2 rearrangements have been reported in a proportion of DLBCLs, where they may be associated with an adverse clinical o
Externí odkaz:
https://doaj.org/article/8e39318de5064d1bb94d3e611de55ce8
Publikováno v:
Acta Oncologica Turcica. 55:103-108
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45c6d09a08972de3a6cda92af42cf559
https://doi.org/10.5505/aot.2022.13008
https://doi.org/10.5505/aot.2022.13008
Autor:
Mehmet Sinan Dal, Bahar Uncu Ulu, Ant Uzay, Olga Meltem Akay, Sevgi Beşışık, Mustafa Nuri Yenerel, Serhat Çelik, Leylagül Kaynar, Orhan Kemal Yücel, Burak Deveci, Mehmet Sönmez, Özgür Mehtap, Hüseyin Saffet Beköz, Cenk Sunu, Ozan Salim, Turgay Ulaş, Sami Kartı, Fevzi Altuntaş, Burhan Ferhanoğlu, Tülin Fırat Tuğlular
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c7c00cd4c281e383f205b4688df81ba
https://avesis.kayseri.edu.tr/publication/details/b6234c55-fa08-48f6-98b5-80650f4ac594/oai
https://avesis.kayseri.edu.tr/publication/details/b6234c55-fa08-48f6-98b5-80650f4ac594/oai
